Aestus to build up ATx09-002 for treatment of neuropathic pain Aestus Therapeutics, Inc. And Prosidion Ltd., a owned subsidiary of Astellas Pharma Inc wholly., announced today a permit agreement providing Aestus with exclusive, world-wide rights to the Prosidion investigational item PSN-357. Aestus will establish the merchandise as ATx09-002, a novel, first-in-class therapeutic for the treating neuropathic pain. Using their proprietary, systems biology engine for the evaluation of genome-level expression data, and animal versions accepted to be good indicators for neuropathic discomfort in patients, Aestus identified ATx09-002, a glycogen phosphorylase inhibitor, as a potential therapeutic for the treatment of neuropathic pain.Among the draft revisions are the following: The suggestion of new categories for learning disorders and a single diagnostic category, autism spectrum disorders which will incorporate the existing diagnoses of autistic disorder, Asperger’s disorder, childhood disintegrative disorder and pervasive developmental disorder . Work group associates have also suggested that the diagnostic term mental retardation be changed to intellectual disability, getting the DSM requirements into alignment with terminology used by other disciplines.